Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Medivation Inc (NASDAQ: MDVN) announced that it was not interested in the $52.50 per share acquisition bid made by Sanofi SA (ADR) (SE: SNY). Citi’s Yigal Nochomovitz maintained a Neutral rating on Medivation, with a price target of $37.
With the process taking a hostile turn, other bids are expected to emerge for Medivation, analyst Yigal Nochomovitz said.
Reasons For Rejection Of Bid
Nochomovitz pointed out that Sanofi’s offer of $52.50 per share was lower than Medivation’s 52-week high of $66.39. Management may have been expecting a higher price given the upcoming release of Phase II data for breast cancer.
Data in HER2 normal ER/PR+ pts is expected in the second half of 2016; and management may see this as an opportunity to extend the value of its XTANDI franchise, Nochomovitz mentioned. The company is also expecting Phase III data for talazoparib in the first half of 2017.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!